Profile of bevacizumab in the treatment of platinum-resistant ovarian cancer: current perspectives
E Clair McClung, Robert M WenhamDepartment of Gynecologic Oncology, H. Lee Moffitt Cancer Center, Tampa, FL, USAAbstract: Patients with platinum-resistant ovarian cancer have progression of disease within 6 months of completing platinum-based chemotherapy. While several chemotherapeutic opt...
Saved in:
Main Authors: | McClung EC (Author), Wenham RM (Author) |
---|---|
Format: | Book |
Published: |
Dove Medical Press,
2016-03-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Bevacizumab improves overall survival in platinum refractory ovarian cancer patients: A retrospective study
by: Kenro Chikazawa, et al.
Published: (2018) -
Profile of vintafolide (EC145) and its use in the treatment of platinum-resistant ovarian cancer
by: Luyckx M, et al.
Published: (2014) -
The leadership of topotecan in the treatment of recurrent platinum-resistant ovarian cancer
by: K. E. Borisov
Published: (2014) -
A phase II study of the combination chemotherapy of bevacizumab and gemcitabine in women with platinum-resistant recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer
by: Shoji Nagao, et al.
Published: (2020) -
Critical appraisal of bevacizumab in the treatment of ovarian cancer
by: Yoshida H, et al.
Published: (2015)